Canada - English - Health Canada

zoetis canada inc - oclacitinib (oclacitinib maleate) - tablet (chewable) - 3.6mg - oclacitinib (oclacitinib maleate) 3.6mg - dogs

Canada - English - Health Canada

zoetis canada inc - oclacitinib (oclacitinib maleate) - tablet (chewable) - 5.4mg - oclacitinib (oclacitinib maleate) 5.4mg - dogs

Canada - English - Health Canada

zoetis canada inc - oclacitinib (oclacitinib maleate) - tablet (chewable) - 16mg - oclacitinib (oclacitinib maleate) 16mg - dogs

United States - English - NLM (National Library of Medicine)

zoetis inc. - oclacitinib maleate (unii: von733l42a) (oclacitinib - unii:99gs5xtb51) - oclacitinib maleate 3.6 mg -  control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 150 mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - maraviroc (unii: md6p741w8a) (maraviroc - unii:md6p741w8a) - maraviroc 300 mg - selzentry is indicated in combination with other antiretroviral agents for the treatment of only ccr5-tropic human immunodeficiency virus type 1 (hiv-1) infection in patients 2 years of age and older weighing at least 10 kg. limitations of use: selzentry is contraindicated in patients with severe renal impairment or esrd (crcl less than 30 ml per minute) who are concomitantly taking potent cyp3a inhibitors or inducers [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to selzentry during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary limited data on the use of selzentry during pregnancy from the apr and case reports are not sufficient to inform a drug-associated risk of birth defects and miscarriage. in animal reproduction studies, no evidence of adverse developmental outcomes was observed with maraviroc. durin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grochem australia pty ltd - imazalil present as the sulfate - water soluble granules - imazalil present as the sulfate imidazole active 750.0 g/kg - fungicide - apple - post-harvest dip | citrus - post-harvest dip | pear - post-harvest dip | potato tuber - blue mould on citrus - p. italicum | blue mould on pome - p. expansum | fusarium dry rot | gangrene - phoma exigua | green mould | silver scurf

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - maraviroc -

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - maraviroc 150mg;   - film coated tablet - 150 mg - active: maraviroc 150mg   excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose opadry blue 85g20583 sodium starch glycolate - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1. the use of other active agents with celsentri is associated with a greater likelihood of treatment response.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - maraviroc 300mg;   - film coated tablet - 300 mg - active: maraviroc 300mg   excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose opadry blue 85g20583 sodium starch glycolate - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1. the use of other active agents with celsentri is associated with a greater likelihood of treatment response.